Market Size of Global Insulin Infusion Pumps Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 3.86 Billion |
| Market Size (2029) | USD 5.07 Billion |
| CAGR (2024 - 2029) | 5.60 % |
| Fastest Growing Market | North America |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Insulin Infusion Pumps Market Analysis
The Global Insulin Infusion Pumps Market size is estimated at USD 3.86 billion in 2024, and is expected to reach USD 5.07 billion by 2029, growing at a CAGR of 5.60% during the forecast period (2024-2029).
The market is estimated to reach USD 4.5 billion by 2027.
The COVID-19 pandemic positively impacted the Insulin Infusion Pumps Market. The SARS-CoV-2, which causes COVID-19, has resulted in over 100 million cases of infection and more than 2 million deaths globally as of February 2021. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19, including an increased risk of severe illness or death. Type-1 diabetes patients are impacted more during COVID-19. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances of getting into serious complications than normal people. The manufacturers of Insulin Infusion Pumps have taken care during COVID-19 to deliver insulin delivery devices to diabetes patients with the help of local governments.
An insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. Insulin infusion pumps reduce the large swings in blood glucose level, lessen pain, and deliver more accurately than injections. The scheduling of meal timings is not required when using pumps. This makes infusion pumps more user-friendly for patients. Insulin therapy is also known as continuous subcutaneous insulin infusion (CSII). It is an efficient and flexible method of insulin delivery. The insulin pump has evolved and is more reliable than it was previously. CSII technology has witnessed numerous technological advancements, like the integration of continuous glucose monitoring with the pump. Now, insulin pumps can control the algorithm automatically delivering the insulin after analyzing the blood glucose reading.
According to International Diabetes Federation (IDF), the adult diabetes population in 2021 was approximately 537 million, which will increase by 643 million in 2030. Approximately 10% of the total diabetes population has Type-1 diabetes, and approximately out of this 10% of people, only 80-90% use insulin delivery devices, but the usage of insulin is rising from time to time; even Type-2 diabetes patients started using the insulin delivery devices during COVID-19.
Technological advancements in insulin delivery devices have increased over time for safer and more accurate insulin administration. In 2021, Medtronic launched an Extended infusion set that leverages advanced materials that help reduce insulin preservative loss and maintains insulin flow and stability. The set is compatible with all MiniMed™ 600 and 700 series insulin pumps. The new tubing connector improves insulin's physical and chemical stability and reliability of infusion site performance and reduces the risk of infusion set occlusion. In addition to the new infusion set, the Medtronic Extended reservoir is also tested and approved to keep insulin stable and safely used for up to 7 days.
Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.
Insulin Infusion Pumps Industry Segmentation
An insulin pump is used to deliver insulin to achieve proper blood sugar control and minimize hypoglycemia's effects. The pump is composed of a pump reservoir similar to an insulin cartridge, a battery-operated pump, and a computer chip that allows the user to control the exact amount of insulin being delivered. The pump is attached to a thin plastic tube (an infusion set) with a soft cannula (or needle) at the end through which insulin passes. The insulin infusion pumps market is segmented by component (pump device, infusion set, and reservoir) and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and Latin America). The report offers the value (in USD million) for the above segments.
| Component (Value and Volume, 2016-2027) | |
| Insulin Pumps | |
| Infusion Sets | |
| Reservoirs |
| Geography | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Global Insulin Infusion Pumps Market Size Summary
The insulin infusion pump market is poised for significant growth, driven by technological advancements and increasing adoption of these devices as alternatives to traditional insulin delivery methods. Insulin pumps offer numerous advantages, such as reducing blood glucose level fluctuations, minimizing pain, and providing more accurate insulin delivery without the need for strict meal timing schedules. This user-friendly approach, combined with continuous subcutaneous insulin infusion (CSII) technology, has made insulin pumps a preferred choice for many patients, particularly those with Type-1 diabetes. The market's expansion is further supported by the integration of continuous glucose monitoring systems, enhancing the reliability and efficiency of insulin delivery. The COVID-19 pandemic has also positively influenced the market, as individuals with diabetes, especially Type-1, faced heightened health risks, prompting increased demand for insulin delivery devices.
North America dominates the insulin infusion pump market, attributed to the easy availability of devices, high consumer awareness, and supportive reimbursement policies. The region's growth is bolstered by the rising prevalence of diabetes and healthcare expenditure, particularly in the United States. Despite the high costs of insulin pumps, improved insurance coverage has facilitated their adoption. The market is characterized by a few major players, including Medtronic PLC, Insulet Corporation, and Tandem Diabetes Care, who are actively involved in partnerships and innovations to enhance product offerings. Recent developments, such as the collaboration between CamDiab and Ypsomed to create an integrated automated insulin delivery system, highlight the ongoing efforts to streamline diabetes management. These factors collectively contribute to the anticipated growth of the insulin infusion pump market during the forecast period.
Global Insulin Infusion Pumps Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Drivers
-
1.3 Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Component (Value and Volume, 2016-2027)
-
2.1.1 Insulin Pumps
-
2.1.2 Infusion Sets
-
2.1.3 Reservoirs
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States (Value and Volume 2016-2027)
-
2.2.1.1.1 By Insulin Pump Devices
-
2.2.1.1.2 By Infusion Sets
-
2.2.1.1.3 By Reservoirs
-
-
2.2.1.2 Canada (Value and Volume, 2016-2027)
-
2.2.1.2.1 By Insulin Pump Devices
-
2.2.1.2.2 By Infusion Sets
-
2.2.1.2.3 By Reservoirs
-
-
2.2.1.3 Rest of North America (Value and Volume, 2016-2027)
-
2.2.1.3.1 By Insulin Pump Devices
-
2.2.1.3.2 By Infusion Sets
-
2.2.1.3.3 By Reservoirs
-
-
-
2.2.2 Asia-Pacific
-
2.2.2.1 Japan (Value and Volume, 2016-2027)
-
2.2.2.1.1 By Insulin Pump Devices
-
2.2.2.1.2 By Infusion Sets
-
2.2.2.1.3 By Reservoirs
-
-
2.2.2.2 South Korea (Value and Volume 2016-2027)
-
2.2.2.2.1 By Insulin Pump Devices
-
2.2.2.2.2 By Infusion Sets
-
2.2.2.2.3 By Reservoirs
-
-
2.2.2.3 China (Value and Volume, 2016-2027)
-
2.2.2.3.1 By Insulin Pump Devices
-
2.2.2.3.2 By Infusion Sets
-
2.2.2.3.3 By Reservoirs
-
-
2.2.2.4 India (Value and Volume, 2016-2027)
-
2.2.2.4.1 By Insulin Pump Devices
-
2.2.2.4.2 By Infusion Sets
-
2.2.2.4.3 By Reservoirs
-
-
2.2.2.5 Australia (Value and Volume, 2016-2027)
-
2.2.2.5.1 By Insulin Pump Devices
-
2.2.2.5.2 By Infusion Sets
-
2.2.2.5.3 By Reservoirs
-
-
2.2.2.6 Vietnam (Value and Volume, 2016-2027)
-
2.2.2.6.1 By Insulin Pump Devices
-
2.2.2.6.2 By Infusion Sets
-
2.2.2.6.3 By Reservoirs
-
-
2.2.2.7 Malaysia (Value and Volume, 2016-2027)
-
2.2.2.7.1 By Insulin Pump Devices
-
2.2.2.7.2 By Infusion Sets
-
2.2.2.7.3 By Reservoirs
-
-
2.2.2.8 Indonesia (Value and Volume, 2016-2027)
-
2.2.2.8.1 By Insulin Pump Devices
-
2.2.2.8.2 By Infusion Sets
-
2.2.2.8.3 By Reservoirs
-
-
2.2.2.9 Philippines (Value and Volume, 2016-2027)
-
2.2.2.9.1 By Insulin Pump Devices
-
2.2.2.9.2 By Infusion Sets
-
2.2.2.9.3 By Reservoirs
-
-
2.2.2.10 Thailand (Value and Volume, 2016-2027)
-
2.2.2.10.1 By Insulin Pump Devices
-
2.2.2.10.2 By Infusion Sets
-
2.2.2.10.3 By Reservoirs
-
-
2.2.2.11 Rest of Asia - Pacific (Value and Volume, 2016-2027)
-
2.2.2.11.1 By Insulin Pump Devices
-
2.2.2.11.2 By Infusion Sets
-
2.2.2.11.3 By Reservoirs
-
-
-
2.2.3 Europe
-
2.2.3.1 United Kingdom (Value and Volume, 2016-2027)
-
2.2.3.1.1 By Insulin Pump Devices
-
2.2.3.1.2 By Infusion Sets
-
2.2.3.1.3 By Reservoirs
-
-
2.2.3.2 France (Value and Volume, 2016-2027)
-
2.2.3.2.1 By Insulin Pump Devices
-
2.2.3.2.2 By Infusion Sets
-
2.2.3.2.3 By Reservoirs
-
-
2.2.3.3 Germany (Value and Volume, 2016-2027)
-
2.2.3.3.1 By Insulin Pump Devices
-
2.2.3.3.2 By Infusion Sets
-
2.2.3.3.3 By Reservoirs
-
-
2.2.3.4 Italy (Value and Volume, 2016-2027)
-
2.2.3.4.1 By Insulin Pump Devices
-
2.2.3.4.2 By Infusion Sets
-
2.2.3.4.3 By Reservoirs
-
-
2.2.3.5 Spain (Value and Volume, 2016-2027)
-
2.2.3.5.1 By Insulin Pump Devices
-
2.2.3.5.2 By Infusion Sets
-
2.2.3.5.3 By Reservoirs
-
-
2.2.3.6 Russia (Value and Volume, 2016-2027)
-
2.2.3.6.1 By Insulin Pump Devices
-
2.2.3.6.2 By Infusion Sets
-
2.2.3.6.3 By Reservoirs
-
-
2.2.3.7 Rest of Europe (Value and Volume, 2016-2027)
-
2.2.3.7.1 By Insulin Pump Devices
-
2.2.3.7.2 By Infusion Sets
-
2.2.3.7.3 By Reservoirs
-
-
-
2.2.4 Latin America
-
2.2.4.1 Mexico (Value and Volume, 2016-2027)
-
2.2.4.1.1 By Insulin Pump Devices
-
2.2.4.1.2 By Infusion Sets
-
2.2.4.1.3 By Reservoirs
-
-
2.2.4.2 Brazil (Value and Volume, 2016-2027)
-
2.2.4.2.1 By Insulin Pump Devices
-
2.2.4.2.2 By Infusion Sets
-
2.2.4.2.3 By Reservoirs
-
-
2.2.4.3 Rest of Latin America (Value and Volume, 2016-2027)
-
2.2.4.3.1 By Insulin Pump Devices
-
2.2.4.3.2 By Infusion Sets
-
2.2.4.3.3 By Reservoirs
-
-
-
2.2.5 Middle-East and Africa
-
2.2.5.1 Saudi Arabia (Value and Volume, 2016-2027)
-
2.2.5.1.1 By Insulin Pump Devices
-
2.2.5.1.2 By Infusion Sets
-
2.2.5.1.3 By Reservoirs
-
-
2.2.5.2 Iran (Value and Volume, 2016-2027)
-
2.2.5.2.1 By Insulin Pump Devices
-
2.2.5.2.2 By Infusion Sets
-
2.2.5.2.3 By Reservoirs
-
-
2.2.5.3 Egypt (Value and Volume, 2016-2027)
-
2.2.5.3.1 By Insulin Pump Devices
-
2.2.5.3.2 By Infusion Sets
-
2.2.5.3.3 By Reservoirs
-
-
2.2.5.4 Oman (Value and Volume, 2016-2027)
-
2.2.5.4.1 By Insulin Pump Devices
-
2.2.5.4.2 By Infusion Sets
-
2.2.5.4.3 By Reservoirs
-
-
2.2.5.5 South Africa (Value and Volume, 2016-2027)
-
2.2.5.5.1 By Insulin Pump Devices
-
2.2.5.5.2 By Infusion Sets
-
2.2.5.5.3 By Reservoirs
-
-
2.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2016-2027)
-
2.2.5.6.1 By Insulin Pump Devices
-
2.2.5.6.2 By Infusion Sets
-
2.2.5.6.3 By Reservoirs
-
-
-
-
Global Insulin Infusion Pumps Market Size FAQs
How big is the Global Insulin Infusion Pumps Market?
The Global Insulin Infusion Pumps Market size is expected to reach USD 3.86 billion in 2024 and grow at a CAGR of 5.60% to reach USD 5.07 billion by 2029.
What is the current Global Insulin Infusion Pumps Market size?
In 2024, the Global Insulin Infusion Pumps Market size is expected to reach USD 3.86 billion.
